Digoxin

Generic Name: Digoxin

Brand Names: Digox, Lanoxin

Drug Type: Small Molecule

Chemical Formula: C_₄₁H_₆₄O_₁₄

CAS Number: 20830-75-5

Unique Ingredient Identifier: 73K4184T59

Background: Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954.

This drug originates from the foxglove plant, also known as the Digitalis plant, studied by William Withering, an English physician and botanist in the 1780s. Prior to this, a Welsh family, historically referred to as the Physicians of Myddvai, formulated drugs from this plant. They were one of the first to prescribe cardiac glycosides, according to ancient literature dating as early as the 1250s.

Indication: Digoxin is indicated in the following conditions: 1) For the treatment of mild to moderate heart failure in adult patients. 2) To increase myocardial contraction in children diagnosed with heart failure. 3) To maintain control ventricular rate in adult patients diagnosed with chronic atrial fibrillation.

In adults with heart failure, when it is clinically possible, digoxin should be administered in conjunction with a diuretic and an angiotensin-converting enzyme (ACE) inhibitor for optimum effects.

Associated Conditions: Myocardial contractility, Ventricular Arrhythmia, Mild to moderate heart failure

Clinical Trials

A Study to Compare How Different Medicines (Rosuvastatin, Digoxin, Metformin, and Furosemide) Are Handled by the Body of Healthy People and People With Liver Cirrhosis

Not Applicable

Completed

Conditions: Liver Cirrhosis

Interventions: Drug: Rosuvastatin
Drug: Digoxin
Drug: Metformin hydrochlorid
Drug: Furosemide

First Posted Date: 2023-02-23

Last Posted Date: 2025-01-22

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 28

Registration Number: NCT05741372

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

A Study in Healthy Men to Test How Well Multiple Doses of BI 1839100 Are Tolerated and How BI 1839100 Influences the Amount of Other Medicines in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo matching BI 1839100
Drug: BI 1839100
Drug: midazolam
Drug: digoxin
Drug: rosuvastatin

First Posted Date: 2023-02-22

Last Posted Date: 2024-11-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 67

Registration Number: NCT05738291

Locations: 🇳🇱
ICON-Groningen-62040, Groningen, Netherlands

Drug Drug Interaction (DDI) Between Supaglutide and Digoxin or Metformin

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Supaglutide injection
Drug: Digoxin
Drug: Metformin

First Posted Date: 2023-01-23

Last Posted Date: 2024-08-05

Lead Sponsor: Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.

Target Recruit Count: 34

Registration Number: NCT05694221

Locations: 🇨🇳
Huashan Hospital, Fudan University, Shanghai, Shanghai, China

Study to Evaluate the Effect of AMG 510 on the Pharmacokinetics (PK) of Digoxin in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: AMG 510
Drug: Digoxin

First Posted Date: 2022-10-28

Last Posted Date: 2025-04-02

Lead Sponsor: Amgen

Target Recruit Count: 14

Registration Number: NCT05598281

Locations: 🇺🇸
Covance Clinical Research Unit, Inc, Daytona Beach, Florida, United States

A Study to Evaluate the Pharmacokinetic Drug-drug Interactions Between VX-548, Midazolam, and Digoxin

Phase 1

Completed

Conditions: Pain

Interventions: Drug: VX-548
Drug: Midazolam
Drug: Digoxin

First Posted Date: 2022-09-15

Last Posted Date: 2024-03-20

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 37

Registration Number: NCT05541471

Locations: 🇺🇸
Baltimore - Early Phase Clinical Unit, Baltimore, Maryland, United States

Left Atrium Reservoir Function Modulation in Patients With Atrial Fibrillation: Digoxin Versus Beta Blocker

Phase 3

Recruiting

Conditions: Atrial Fibrillation
Left Atrial Rhythm

Interventions: Drug: Digoxin 0.25 mg
Drug: Bisoprolol

First Posted Date: 2022-09-14

Last Posted Date: 2022-09-16

Lead Sponsor: University of Monastir

Target Recruit Count: 30

Registration Number: NCT05540600

Locations: 🇹🇳
Fattouma Bourguiba University hospital, Monastir, Tunisia

A Phase 1, Drug-Drug Interaction Study of TBAJ-876 in Healthy Adults

Phase 1

Completed

Conditions: Multi Drug Resistant Tuberculosis
Drug Sensitive Tuberculosis
Pulmonary Disease
Drug-resistant Tuberculosis
Mycobacterium Tuberculosis Infection
Tuberculosis, Pulmonary
Tuberculosis